While metastatic cancer accounts for an overwhelming 90% of the 10 million global cancer deaths each year, there is a powerful story of science and survival emerging from the latest statistics on prevalence, survival, and breakthrough treatments.
Key Takeaways
- In 2023, approximately 612,390 new cases of metastatic cancer were diagnosed in the US across all primary sites, accounting for 18% of all cancer diagnoses
- Globally, metastatic breast cancer affects over 1.2 million women annually, with 70% presenting as stage IV at diagnosis in low-income countries
- The prevalence of metastatic lung cancer in the US reached 140,000 patients living with the disease in 2022, up 25% from 2010
- The 5-year relative survival rate for metastatic breast cancer (stage IV) is 31% in the US (2014-2020 data)
- For distant metastatic lung cancer, median survival is 8.4 months, with 7% 5-year survival (SEER 2017-2021)
- Metastatic colorectal cancer 5-year survival: 15%, improved from 10% in 2000 (US data)
- In 2022, metastatic cancer caused 168,000 deaths in the US, 29% of all cancer mortality
- Globally, metastatic cancers account for 90% of the 10 million cancer deaths yearly (2020)
- Metastatic lung cancer mortality: 125,000 US deaths/year, 80% of lung cancer deaths
- Checkpoint inhibitors achieve 20% ORR in metastatic melanoma, with 50% 5-year OS in responders
- In metastatic NSCLC, pembrolizumab monotherapy yields 45% ORR for PD-L1 high, mPFS 10.3 months
- Regorafenib in metastatic CRC post 2nd line: 1.9% OS benefit, mOS 6.4 vs 5.0 months
- 80% of metastatic cancers linked to smoking, alcohol, obesity, infection, or environmental factors
- BRCA1/2 mutations increase metastatic breast cancer risk 72%, lifetime risk 55-72%
- Smoking causes 85% of metastatic lung cancers, RR 15-30 for heavy smokers
Metastatic cancer is alarmingly common but survival rates remain low.
Incidence & Prevalence
1In 2023, approximately 612,390 new cases of metastatic cancer were diagnosed in the US across all primary sites, accounting for 18% of all cancer diagnoses
Verified2Globally, metastatic breast cancer affects over 1.2 million women annually, with 70% presenting as stage IV at diagnosis in low-income countries
Verified3The prevalence of metastatic lung cancer in the US reached 140,000 patients living with the disease in 2022, up 25% from 2010
Verified4In Europe, metastatic colorectal cancer incidence stands at 185,000 cases per year, with a 5-year prevalence of 450,000 patients
Directional5Metastatic prostate cancer comprises 30% of all prostate cancer cases at diagnosis, affecting 48,000 US men yearly
Single source6Among pancreatic cancers, 53% are metastatic at initial diagnosis, totaling 28,000 cases in the US in 2023
Verified7Metastatic melanoma incidence in Australia is 15.7 per 100,000, with 2,500 stage IV cases annually
Verified8In 2022, 90% of ovarian cancers are diagnosed as metastatic (stage III/IV), equating to 19,800 US cases
Verified9Metastatic kidney cancer prevalence in the EU is 120,000 patients, with 85,000 new metastatic cases yearly
Directional10US bladder cancer metastatic cases number 17,000 annually, representing 5% of diagnoses but 50% of deaths
Single source11Globally, 70% of liver cancers are metastatic at diagnosis, with 410,000 stage IV cases in 2020
Verified12Metastatic non-Hodgkin lymphoma affects 25,000 new US patients yearly, 40% of all NHL cases
Verified13In 2023, metastatic gastric cancer incidence in Asia was 450,000 cases, 80% of global total
Verified14US metastatic thyroid cancer cases: 12,000 yearly, rising 3% annually since 2010
Directional15Metastatic esophageal cancer comprises 60% of diagnoses, 18,000 US cases in 2023
Single source16Brain metastases from lung cancer occur in 40% of cases, affecting 50,000 US patients annually
Verified17Metastatic uterine cancer incidence: 12,500 US cases yearly, 20% stage IV
Verified18Globally, metastatic cervical cancer: 250,000 cases/year, 90% in developing countries
Verified19US metastatic multiple myeloma prevalence: 85,000 patients in 2022
Directional20Metastatic head and neck cancer: 15% of cases, 13,000 US annually
Single source21In 2023, metastatic sarcoma incidence worldwide: 35,000 cases
Verified22US metastatic germ cell tumors: 2,500 cases/year, mostly testicular origin
Verified23Metastatic adrenocortical carcinoma: rare, 200 US cases/year, 70% stage IV
Verified24Global metastatic mesothelioma: 30,000 cases/year, linked to asbestos
Directional25US metastatic neuroendocrine tumors prevalence: 100,000 patients
Single source26Metastatic penile cancer: 500 US cases/year, 50% advanced
Verified27In 2022, metastatic vulvar cancer: 1,200 US cases
Verified28Metastatic anal cancer incidence: 8,000 US/year, rising 2%/year
Verified29Global metastatic Kaposi sarcoma: 25,000 cases/year in HIV patients
Directional30US metastatic chordoma prevalence: 1,000 patients
Single sourceIncidence & Prevalence Interpretation
These statistics paint a chilling portrait of a world stage where cancer has already taken its final, most devastating bow in far too many patients by the time the curtain of diagnosis finally rises.
Mortality Statistics
1In 2022, metastatic cancer caused 168,000 deaths in the US, 29% of all cancer mortality
Verified2Globally, metastatic cancers account for 90% of the 10 million cancer deaths yearly (2020)
Verified3Metastatic lung cancer mortality: 125,000 US deaths/year, 80% of lung cancer deaths
Verified4Colorectal metastatic disease causes 52% of CRC deaths, 27,000 US annually
Directional5Pancreatic metastatic cancer mortality rate: 50,000 US/year, 83% of pancreatic deaths
Single source6Breast cancer metastatic deaths: 42,000 US/year, despite early detection efforts
Verified7Prostate metastatic mortality: 34,000 US/year, 50% of prostate deaths
Verified8Liver metastatic cancer deaths: 29,000 US/year, 75% metastatic at death
Verified9Ovarian metastatic mortality: 12,700 US/year, 70% stage III/IV
Directional10Melanoma metastatic deaths: 7,650 US/year, down 20% since 2015
Single source11Kidney metastatic cancer mortality: 14,000 US/year
Verified12Bladder distant met mortality: 17,000 US/year, 50% of bladder deaths
Verified13Esophageal metastatic deaths: 16,500 US/year, 85% metastatic
Verified14Gastric metastatic mortality: 11,000 US/year, global 769,000
Directional15Non-Hodgkin lymphoma met deaths: 20,000 US/year
Single source16Thyroid distant met mortality: 1,100 US/year
Verified17Endometrial met mortality: 13,000 US/year
Verified18Cervical met deaths: 4,000 US/year
Verified19Multiple myeloma deaths: 35,000 US/year, mostly advanced
Directional20Head/neck met mortality: 10,000 US/year
Single source21Soft tissue sarcoma met deaths: 5,000 US/year
Verified22Testicular met mortality: 400 US/year
Verified23Mesothelioma deaths: 3,000 US/year, nearly all metastatic
Verified24Neuroendocrine met mortality: 8,000 US/year
Directional25Anal cancer met deaths: 900 US/year
Single source26Penile cancer met mortality: 300 US/year
Verified27Vulvar met deaths: 1,100 US/year
Verified28Kaposi sarcoma deaths: 500 US/year
Verified29Global chordoma met mortality: 200/year
DirectionalMortality Statistics Interpretation
Despite remarkable advances in early detection and targeted treatments, metastatic cancer remains the grim and final arbiter of most cancer deaths, a sobering reality underscored by the fact that it claims the vast majority of lives across nearly every cancer type.
Risk Factors & Prevention
180% of metastatic cancers linked to smoking, alcohol, obesity, infection, or environmental factors
Verified2BRCA1/2 mutations increase metastatic breast cancer risk 72%, lifetime risk 55-72%
Verified3Smoking causes 85% of metastatic lung cancers, RR 15-30 for heavy smokers
Verified4Obesity raises metastatic colorectal cancer risk by 30%, per 5 BMI units
Directional5HPV infection responsible for 70% metastatic cervical/oropharyngeal cancers
Single source6Chronic HBV/HCV leads to 80% metastatic liver cancers
Verified7Age >65 doubles metastatic prostate cancer risk, 60% cases in this group
Verified8Diabetes increases pancreatic metastatic cancer risk 1.9-fold
Verified9UV exposure causes 90% metastatic melanomas, RR 2.0 for sunburn history
Directional10Family history triples ovarian metastatic cancer risk, 10-15% hereditary
Single source11Smoking elevates renal cell met risk 50%
Verified12Arsenic in water linked to 20% bladder met cases in endemic areas
Verified13Alcohol >3 drinks/day raises esophageal met risk 5-fold
Verified14H. pylori infection causes 89% non-cardia gastric met cancers
Directional15Immunosuppression increases NHL met risk 100-fold in transplant patients
Single source16Radiation exposure raises thyroid met risk, RR 7.7 post-Chernobyl
Verified17Lynch syndrome accounts for 3% met endometrial cancers
Verified18HIV increases anal met cancer risk 100-fold
Verified19Asbestos exposure causes 80% pleural mesothelioma mets, latency 20-50 years
Directional20Multiple myeloma risk doubles after 65, monoclonal gammopathy precedes 1%/year
Single source21Betel nut chewing linked to 50% oral cavity met in Asia
Verified22Prior chemo increases therapy-related met MDS/AML risk 1-5%
Verified23BRCA2 mutations confer 20% met pancreatic cancer lifetime risk
Verified24Shift work disrupts circadian rhythm, 1.2-fold met breast risk
Directional25Red/processed meat intake >500g/week raises met CRC risk 18%
Single source26Talc use in ovaries linked to 30% increased met ovarian risk
VerifiedRisk Factors & Prevention Interpretation
While the grim reaper’s business model thrives on vice, genetics, and modern life, these statistics starkly remind us that the map of metastatic cancer is largely charted by our choices, our exposures, and the cards we are dealt at birth.
Survival & Prognosis
1The 5-year relative survival rate for metastatic breast cancer (stage IV) is 31% in the US (2014-2020 data)
Verified2For distant metastatic lung cancer, median survival is 8.4 months, with 7% 5-year survival (SEER 2017-2021)
Verified3Metastatic colorectal cancer 5-year survival: 15%, improved from 10% in 2000 (US data)
Verified4Stage IV prostate cancer 5-year survival: 32%, median OS 42 months with modern therapies
Directional5Metastatic pancreatic cancer median survival: 11 months, 3% 5-year survival rate
Single source6Distant metastatic melanoma 5-year survival: 30%, up from 15% pre-immunotherapy era
Verified7Stage IV ovarian cancer 5-year survival: 17%, median PFS 12 months with PARP inhibitors
Verified8Metastatic renal cell carcinoma 5-year survival: 15%, improved to 25% with TKIs/ICIs
Verified9Distant bladder cancer 5-year survival: 6%, median OS 14 months
Directional10Metastatic hepatocellular carcinoma median survival: 11 months with sorafenib, 3% 5-year
Single source11Stage IV non-Hodgkin lymphoma 5-year survival: 64% for DLBCL subtype
Verified12Metastatic gastric cancer median OS: 11 months with chemo, 5-year survival <5%
Verified13Distant thyroid cancer 5-year survival: 54%, better for follicular vs anaplastic
Verified14Metastatic esophageal cancer 5-year survival: 6%, median OS 10 months
Directional15Brain metastases overall median survival: 12 months, varies by primary (lung 8mo, breast 15mo)
Single source16Stage IV endometrial cancer 5-year survival: 19%
Verified17Metastatic cervical cancer 5-year survival: 18%, median OS 16 months with bevacizumab
Verified18Multiple myeloma stage III 5-year survival: 50%, median OS 62 months
Verified19Metastatic head/neck squamous cell 5-year survival: 40%
Directional20Soft tissue sarcoma metastatic 5-year survival: 18%
Single source21Metastatic testicular cancer 5-year survival: 73% with salvage chemo
Verified22Adrenocortical carcinoma stage IV median OS: 14 months, 5-year survival 13%
Verified23Metastatic mesothelioma 5-year survival: 10%, median OS 13 months with pembro
Verified24Neuroendocrine tumor metastatic grade 3 5-year survival: 20%
Directional25Metastatic penile cancer 5-year survival: 11%
Single source26Vulvar cancer stage IV 5-year survival: 15%
Verified27Anal cancer metastatic 5-year survival: 20%, median OS 22 months
Verified28Kaposi sarcoma metastatic 5-year survival: 25% in HIV+ patients on ART
Verified29Chordoma metastatic 5-year survival: 40%
DirectionalSurvival & Prognosis Interpretation
Modern medicine has managed to turn some metastatic cancers into chronic conditions while others remain brutally stubborn adversaries, proving that while our weapons are improving, the battle is still defined by where it starts.
Treatment Effectiveness
1Checkpoint inhibitors achieve 20% ORR in metastatic melanoma, with 50% 5-year OS in responders
Verified2In metastatic NSCLC, pembrolizumab monotherapy yields 45% ORR for PD-L1 high, mPFS 10.3 months
Verified3Regorafenib in metastatic CRC post 2nd line: 1.9% OS benefit, mOS 6.4 vs 5.0 months
Verified4Enzalutamide in mCRPC: 76% radiographic PFS at 12 months vs 38% placebo
Directional5FOLFIRINOX in metastatic pancreatic cancer: mOS 11.1 vs 6.8 months gemcitabine
Single source6PARP inhibitor olaparib in BRCA+ metastatic breast: 42% ORR, mPFS 7.0 months
Verified7Nivolumab in metastatic RCC: 25% ORR, mOS 25.2 months
Verified8Atezolizumab + bevacizumab in metastatic HCC: 30% ORR, mOS 19.2 months
Verified9CAR-T axicabtagene ciloleucel in DLBCL met: 83% ORR, 58% CR
Directional10Trastuzumab deruxtecan in HER2+ met breast: 79% ORR, mPFS 16.4 months
Single source11Osimertinib in EGFR+ met NSCLC: 80% ORR, mPFS 18.9 months
Verified12Sunitinib in met GIST: 49% clinical benefit rate, mPFS 24 weeks
Verified13Ipilimumab + nivolumab in met melanoma: 52% ORR, 72% 2-year OS
Verified14Bevacizumab + chemo in met ovarian: mPFS 18.5 vs 16.8 months
Directional15Daratumumab + bortezomib in met myeloma: 81% ORR, mPFS NR at 7.5 months
Single source16Cetuximab + chemo in KRAS wt met CRC: mPFS 9.9 vs 8.4 months
Verified17Afatinib in HER2 mut met NSCLC: 64% DCR, mPFS 4.2 months
Verified18Lenvatinib + everolimus in met RCC post-VEGF: mPFS 14.6 vs 5.5 months
Verified19Ramucirumab in met gastric post-chemo: mOS 9.6 vs 7.4 months
Directional20Alectinib in ALK+ met NSCLC: 81% ORR, mPFS 11.2 months
Single source21High-dose chemo + ASCT in met testicular: 60% CR rate
Verified22Pembrolizumab in MSI-H met solid tumors: 42% ORR
Verified23Entrectinib in ROS1+ met NSCLC: 77% ORR, mPFS 19 months
Verified24Niraparib maintenance in met ovarian: mPFS 21 vs 5.5 months
Directional25Tisagenlecleucel in DLBCL: 52% ORR, 40% CR
Single source26Selpercatinib in RET+ met thyroid/NSCLC: 64% ORR
Verified27Tucatinib + trastuzumab/capecitabine in HER2+ met breast brain met: 47% intracranial ORR
VerifiedTreatment Effectiveness Interpretation
This kaleidoscope of data reveals that while modern oncology's targeted strikes can be spectacular, they are often precarious victories in a grinding war of attrition against metastasis.
Sources & References
- Reference 1SEERseer.cancer.govVisit source
- Reference 2WHOwho.intVisit source
- Reference 3CANCERcancer.orgVisit source
- Reference 4ECec.europa.euVisit source
- Reference 5CANCERcancer.govVisit source
- Reference 6AIHWaihw.gov.auVisit source
- Reference 7GLOBOCANglobocan.iarc.frVisit source
- Reference 8PUBMEDpubmed.ncbi.nlm.nih.govVisit source
- Reference 9NCBIncbi.nlm.nih.govVisit source
- Reference 10IARCiarc.who.intVisit source
- Reference 11RAREDISEASESrarediseases.orgVisit source
- Reference 12CDCcdc.govVisit source
- Reference 13NEJMnejm.orgVisit source